

# United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO	).	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/772,719		01/30/2001	Jan Zavada	D-0021, 3A-2	1371	
24988	7:	590 10/03/2003		EXAMINER		
LEONA I			WHISENANT, ETHAN C			
		NIA, SUITE 450 SCO,  CA    94104-1840		ART UNIT	PAPER NUMBER	
		•		1634		
				DATE MAILED: 10/03/2003		

Please find below and/or attached an Office communication concerning this application or proceeding.

		Applicati	on No.	Applicant(s)				
		09/772,7		ZAVADA ET AL.				
	Office Action Summary	Examine		Art Unit				
	•							
Ethan Whisenant, Ph.D. 1634  The MAILING DATE of this communication appears on the cover sheet with the correspondence address								
Period for Reply								
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).  Status								
1)⊠	Responsive to communication(s) filed	on <u>02 June 2003</u>						
2a)⊠	This action is <b>FINAL</b> . 2b)	) ☐ This action is	non-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.								
Disposition of Claims								
4)⊠	Claim(s) <u>48-69</u> is/are pending in the ap	•						
-, -	4a) Of the above claim(s) is/are withdrawn from consideration.							
	Claim(s) is/are allowed.							
	6)⊠ Claim(s) <u>48-69</u> is/are rejected.							
	Claim(s) is/are objected to.	.,						
	Claim(s) are subject to restriction  ion Papers	n and/or election r	equirement.					
	•	xaminer						
9) The specification is objected to by the Examiner.  10) The drawing(s) filed on is/are: a) □ accepted or b) □ objected to by the Examiner.								
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).								
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.								
If approved, corrected drawings are required in reply to this Office action.								
12) ☐ The oath or declaration is objected to by the Examiner.								
Priority under 35 U.S.C. §§ 119 and 120								
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).								
a) ☐ All b) ☐ Some * c) ☐ None of:								
	1. Certified copies of the priority documents have been received.							
	2. Certified copies of the priority documents have been received in Application No							
<ul> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>								
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).								
a) ☐ The translation of the foreign language provisional application has been received. 15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.								
Attachment(s)								
2) Notice	ce of References Cited (PTO-892) ce of Draftsperson's Patent Drawing Review (PTO mation Disclosure Statement(s) (PTO-1449) Pape			mary (PTO-413) Paper No(s) nal Patent Application (PTO-152)				

Application/Control Number: 09/772,719 Page 2

Art Unit: 1634

# FINAL REJECTION

1. The applicant's Response (filed 02 JUN 03) to the Office Action has been entered. Following the entry of the claim amendment(s), Claim(s) 48-69 is/are pending. Rejections and/or objections not reiterated from the previous office action are hereby withdrawn. The following rejections and/or objections are either newly applied or reiterated. They constitute the complete set presently being applied to the instant application.

## 35 USC § 112 - 1st Paragraph

**2.** The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

# CLAIM REJECTIONS UNDER 35 USC § 112-1ST PARAGRAPH

**3.** Claim(s) 58 is/are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

In the instant case, the applicant has disclosed that an increase in MN protein is diagnostic of neoplastic and/or preneoplastic diseases and gives numerous examples including renal carcinoma. In addition there is basis for the patenting of a generic RT-PCR process to detect an increase in MN gene expression, however, there is not explicit elaboration of the claimed RT-PCR (i.e. the primers) to detect an increase in MN gene expression. The examiner has followed the General Principle governing compliance with the written description requirement for applications outlined in the previous office action (i.e. the office action mailed 02 JAN 03 ).

Art Unit: 1634

#### NONSTATUTORY DOUBLE PATENTING

4. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970);and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

**5.** Claim(s) 48-51 is/are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claim 1-3 of U.S. Patent No. 6,027,887.

Although the conflicting claims are not identical, they are not patentably distinct from each other. Claims 1-3 of U.S. Patent No. 6,027,887 teach all of the limitations of Claims 48-51. Claims 1-3 of U.S. Patent No. 6,027,887 are coextensive in scope with those of Claims 48-51 of the instant application and the granting of as patent thereon would allow the unjustified or improper timewise extension of the "right to exclude" previously granted to the applicant in U.S. Patent No. 6,027,887.

**6.** Claim(s) 52-57 and 59-69 is/are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claim 1-3 of U.S. Patent No. 6,027,887 in view of Samid [US Patent No.: 5,605,930 (1997)].

Claims 1-10 of U.S. Patent No. 6,027,887 teach all of the limitations of Claim 52 except this patent's claims do not teach that the nucleic acid based assay is a PCR based assay as recited in Claims 52, however, as RT-PCR (a PCR based assay) and it use to detect abnormal gene expression, was well known at the time of the invention as evidenced by Samid (see the entire paragraph in Column

Application/Control Number: 09/772,719 Page 4

Art Unit: 1634

110, beginning at about line 15), it would have been, absent an unexpected result, *prima facie* obvious to one of ordinary skill in the art at the time of the invention to modify the method taught by Claims 1-10 of U.S. Patent No. 6,027,887 with the teachings of Samid. The ordinary artisan would have been motivated to make this modification in order to confirm the results of the assay in Claims 1-10 of U.S. Patent No. 6,027,887 as suggested by Samid.

#### RESPONSE TO APPLICANT'S AMENDMENT/ ARGUMENTS

**7.** Applicant's arguments with respect to the claimed invention have been fully and carefully considered but are not deemed to be persuasive.

The applicant presents numerous paragraphs of arguments including reasoning as to why the McKiernan et al. patent [US 6,087,098 (2000)] lacks utility and is not enabled. In response, the examiner must admit that he agrees with the applicant's reasoning, however, all US patents, by law, are presumed valid. Also note that "the burden of establishing invalidity of a patent or any claim thereof shall rest on the party asserting such invalidity."

As regards the declaration of an interference with the claims of the McKiernan et al. patent [US 6,087,098 (2000)], the examiner finds the applicant's arguments unpersuasive. McKiernan et al. is claiming a patentably distinct species which falls within the broader scope of the instant claims and those of US Patent No. 6,027,887, In addition, as regards the presumed count (i.e. Claim 1 of US 6,087,098) of an interference, the applicant's disclosure as originally filed fails to meet the written description requirement of 35 U.S.C. 112, first paragraph. Therefore it would be improper for the examiner to declare an interference.

## CONCLUSION

**8.** Claim(s) 48-69 is/are rejected and/or objected to for the reason(s) set forth above.

Application/Control Number: 09/772,719

Page 5

Art Unit: 1634

**9.** Applicant's amendment necessitated the new grounds of rejection. Accordingly, **THIS ACTION IS MADE FINAL.** See M.P.E.P. § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 C.F.R. § 1.136(a).

A SHORTENED STATUTORY PERIOD FOR RESPONSE TO THIS FINAL ACTION IS SET TO EXPIRE THREE MONTHS FROM THE DATE OF THIS ACTION. IN THE EVENT A FIRST RESPONSE IS FILED WITHIN TWO MONTHS OF THE MAILING DATE OF THIS FINAL ACTION AND THE ADVISORY ACTION IS NOT MAILED UNTIL AFTER THE END OF THE THREE-MONTH SHORTENED STATUTORY PERIOD, THEN THE SHORTENED STATUTORY PERIOD WILL EXPIRE ON THE DATE THE ADVISORY ACTION IS MAILED, AND ANY EXTENSION FEE PURSUANT TO 37 C.F.R. § 1.136(a) WILL BE CALCULATED FROM THE MAILING DATE OF THE ADVISORY ACTION. IN NO EVENT WILL THE STATUTORY PERIOD FOR RESPONSE EXPIRE LATER THAN SIX MONTHS FROM THE DATE OF THIS FINAL ACTION.

**10.** Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ethan Whisenant, Ph.D. whose telephone number is (703) 308-6567. The examiner can normally be reached Monday-Friday from 8:30AM -5:30PM EST or any time via voice mail. If repeated attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, W. Gary Jones, can be reached at (703) 308-1152.

The fax number for this Examiner is (703) 746-8465. Before faxing any papers please inform the examiner to avoid lost papers. Please note that the faxing of papers must conform with the Notice to Comply published in the Official Gazette, 1096 OG 30 (November 15, 1989). Any inquiry of a general nature or relating to the status of this application should be directed to the group receptionist whose telephone number is (703) 308-0196.

ETHAN WHISENANT PRIMARY EXAMINER